Despite the above limitations, the overall impression is that BNP/NT-proBNP-guided treatment may be useful, and this is reflected in the current American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) HF guidelines, which are in favor of the use of NPs to guide evidence-based treatment [19]. The gene discussed is NPPB; the disease is hydrops fetalis.